NovelMed Therapeutics
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS8
PHASE 3 / 2-30
RECRUITING0
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO88%
Delay Index: of 8 active trials registered more than a year ago, 7 have moved their primary completion (readout) date by more than 6 months since first registration (median +52.0 months). See all sponsors →
Open NovelMed Therapeutics on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| NM8074 NCT05646524 |
P2 | Not yet recruiting | Paroxysmal Nocturnal Hemoglobinuria | 12 | 2027-08 (+42 mo) |
| NM8074 NCT05731050 |
P2 | Not yet recruiting | PNH - Paroxysmal Nocturnal Hemoglobinuria | 6 | 2027-09 (+13 mo) |
| NM8074 NCT06226662 |
P2 | Not yet recruiting | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 12 | 2027-10 (+12 mo) |
| NM8074 NCT06887738 |
P2 | Not yet recruiting | Dermatomyositis | 8 | 2027-11 |
| NM8074 NCT05646563 |
P2 | Not yet recruiting | Paroxysmal Nocturnal Hemoglobinuria | 12 | 2029-07 (+65 mo) |
| NM8074 NCT05647811 |
P1/2 | Not yet recruiting | C3 Glomerulopathy | 18 | 2029-08 (+60 mo) |
| NM8074 NCT05684159 |
P2 | Not yet recruiting | aHUS - Atypical Hemolytic Uremic Syndrome | 12 | 2030-04 (+56 mo) |
| NM8074 NCT06454110 |
P2 | Not yet recruiting | IgA Nephropathy | 10 | 2030-12 (+52 mo) |